Yantai Zhenghai Bio-tech (300653.SZ): The company's calcium-silicon biological ceramic bone repair materials are expected to apply for registration within the year.

On July 19th, Gelunhui reported that an investor had asked Zhenghai Bio-Tech (300653.SZ) through an interactive platform: How is the promotion of bioceramic bones overseas? Is it authorized or self-promoted? When will calcium-silicon bioceramic bone repair materials be registered and when can they be launched for sale? Zhenghai Bio-Tech (300653.SZ) replied: Hello! According to relevant regulations, the medical device product requires the sale license of the country where it is sold overseas. As the first domestic bone filling product containing rhBMP-2 uniquely bound with collagen, Activated Bio-Bone has high innovation and it has long-term export potential.

Gelonghui FinanceJul 19 03:21 ET

Yantai Zhenghai Bio-Tech (300653.SZ) has spent a total of 14.9936 million yuan to repurchase 662.2 thousand shares.

On July 2nd, Gelunhui reported that Yantai Zhenghai Bio-Tech (300653.SZ) has repurchased 662,150 shares of the company through a stock repurchase special securities account by centralized competitive trading as of June 30, 2024, accounting for 0.3679% of the total equity of the company. The highest fill price was 24.83 yuan/share, and the lowest fill price was 20.27 yuan/share. The total amount paid was 14.9936 million yuan (excluding transaction fees).

Gelonghui FinanceJul 2 05:25 ET

The Three-year Underlying Earnings Growth at Yantai Zhenghai Biotechnology (SZSE:300653) Is Promising, but the Shareholders Are Still in the Red Over That Time

Simply Wall StJun 20 22:57 ET

Yantai Zhenghai Bio-Tech (300653.SZ): During the use of active biological bone, doctors decide on the selection of internal fixation devices based on clinical needs. Currently, no related supporting medical devices are provided.

Zhenghai Bio-tech (300653.SZ) stated on the investor interaction platform that the company's active biological bone product is mainly used to fill bone defects caused by trauma or surgery that do not affect the stability of bone structure. During the use of active biological bone, doctors determine the choice of internal fixation devices according to clinical needs, and the company currently does not provide relevant supporting medical devices. Umbilical cord mesenchymal stem cells are currently in the product process validation stage. The company will continue to cultivate in the field of regenerative medicine, actively researching and developing products and technologies including signal molecules, seed cells, additive manufacturing, genetic engineering, and synthetic biology to create medical devices and treatments.

Gelonghui FinanceJun 7 04:20 ET

Yantai Zhenghai Bio-Tech (300653.SZ) equity distribution in 2023: 8.01804 yuan per 10 shares.

Zhenghai Bio-Tech (300653.SZ) announced its annual equity distribution plan for 2023: based on the company's existing total share capital after deducting the repurchased shares, it will distribute RMB 8.01804 in cash per 10 shares to all shareholders. The equity distribution share registration date is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.

Zhitong FinanceJun 5 08:37 ET

Yantai Zhenghai Bio-tech (300653.SZ) has repurchased 0.1679% of its shares, at a cumulative cost of 7.1857 million yuan.

On June 5th, Gelunhui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced that as of May 31, 2024, the company repurchased 302,300 shares of the company's stock through a share repurchase special securities account through centralized bidding trading, accounting for 0.1679% of the company's total share capital, with a highest transaction price of 24.83 yuan/share, a lowest transaction price of 22.90 yuan/share, and a total amount paid of 7,185,656.74 yuan (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.

Gelonghui FinanceJun 5 03:45 ET